Ann Lab Med.  2018 Jan;38(1):51-53. 10.3343/alm.2018.38.1.51.

Is It Necessary to Repeat Fecal Occult Blood Tests with Borderline Results for Colorectal Cancer Screening?

• Lee E
• Lee Y

• KMID: 2397602
• DOI: http://doi.org/10.3343/alm.2018.38.1.51

Abstract

The fecal immunochemical test (FIT) is the initial non-invasive investigation of choice for population-based colorectal cancer (CRC) screening. We evaluated the positivity rate in repeated tests using the same fecal specimen that showed borderline results in the FIT. A total of 6,465 patients were tested with the FIT in a tertiary-care hospital from July to December 2016. FIT was done using OC-Sensor PLEDIA (Eiken Chemical Co., Tokyo, Japan). Among 6,465 patients, 364 (5.6%) patients showed a positive FIT result of over 20 µg Hb/g feces. A total of 112 (1.7%) patients showed borderline scores of 10.2-20 µg Hb/g feces, and 5,989 (92.6%) patients showed negative results of less than 10 µg Hb/g feces. Among the 101 repeat-tested patients, 19 (18.8%) of the patients' scores converted to levels above the positive cut-off threshold. Repeated results of 19 patients showed score elevations from 20.2 to 68 µg Hb/g feces. These results suggest that it is most important to analyze properly prepared samples, even if only once. Therefore, the laboratory staff should ensure the proper preparation of stool specimens for FIT. Laboratory directors should choose the best cut-off value for detecting CRC at their respective institutions.

Keyword

Colorectal cancer; Fecal immunochemical test; Cut-off value

MeSH Terms

Colorectal Neoplasms*
Feces
Humans
Mass Screening*
Occult Blood*

Figure

• 

  Fig. 1 First and repeated test results for fecal immunochemical test in 101 patients showing borderline scores.

Reference

1. Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, et al. Screening for colorectal cancer and evolving issues for physicians and patients: a Review. JAMA. 2016; 316:2135–2145. PMID: 27893135.

2. Force USPST. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016; 315:2564–2575. PMID: 27304597.

3. Chiang TH, Chuang SL, Chen SL, Chiu HM, Yen AM, Chiu SY, et al. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program. Gastroenterology. 2014; 147:1317–1326. PMID: 25200099.

4. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366:697–706. PMID: 22356323.

5. Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE. Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev. 2015; 24:24–26. PMID: 24584197.

6. Website: http://www.worldendo.org/wp-content/uploads/2016/08/weo_expert_working_group_fit_discussion_doc_no5_pu.pdf. 29 Aug 2017.

7. Passamonti B, Malaspina M, Fraser CG, Tintori B, Carlani A, D’Angelo V, et al. A comparative effectiveness trial of two faecal immunochemical tests for haemoglobin (FIT). Assessment of test performance and adherence in a single round of a population-based screening programme for colorectal cancer. Gut. 2016; 12. 14. pii: gutjnl-2016-312716. DOI: 10.1136/gutjnl-2016-312716. [Epub ahead of print].

8. Fraser CG, Allison JE, Halloran SP, Young GP. Expert working group on fecal immunochemical tests for hemoglobin CCSCWEO. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012; 104:810–814. PMID: 22472305.

9. Kapidzic A, van Roon AH, van Leerdam ME, van Vuuren AJ, van Ballegooijen M, Lansdorp-Vogelaar I, et al. Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut. 2017; 66:118–123. PMID: 26370109.

10. van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar sive Droste JS, et al. Similar fecal immunochemical test results in screening and referral colorectal cancer. World J Gastroenterol. 2012; 18:5397–5403. PMID: 23082056.

11. Akram A, Gupta S. Fecal immunochemical testing: a sensitive and sustainable approach for population colorectal cancer screening? Gastroenterology. 2016; 151:554–555. PMID: 27477339.

12. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149:638–658. PMID: 18838718.

13. van Roon AH, Goede SL, van Ballegooijen M, van Vuuren AJ, Looman CW, Biermann K, et al. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013; 62:409–415. PMID: 22387523.

14. Website: National Health Insurance Service Ilsan Hospital Research Report. 13 Jan 2017. Available at:http://lib.nhis.or.kr/search/detail/CATXAZ000000016556.